There are currently 1471 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas
Conditions: Advanced Solid Malignancies
Register for Updates
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
NCT06190717
Recruiting
This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
07/08/2025
Locations: Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas
Conditions: Diabetes, End Stage Renal Disease
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Baylor University Medical Center, Dallas, Texas
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Site 67, Dallas, Texas
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
NCT07009860
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD. * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/08/2025
Locations: Altimmune Clinical Study Site, Dallas, Texas
Conditions: Alcohol Liver Disease
Register for Updates
DBS of the SCC for the Treatment of Medically Refractory CLBP
NCT04085406
Recruiting
The purpose of this study is to evaluate the feasibility and preliminary efficacy of deep brain stimulation of the subgenual cingulate cortex for the treatment of chronic medically-refractory low back pain using a randomized double-blind crossover design.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
07/07/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Chronic Low-back Pain
Register for Updates
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
NCT05048797
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
Gender:
ALL
Ages:
Between 18 years and 123 years
Trial Updated:
07/07/2025
Locations: Research Site, Dallas, Texas
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: Neuro-Oncology Associates, Dallas, Texas +1 locations
Conditions: H3 K27M, Glioma
Register for Updates
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932
Recruiting
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Multiple Myeloma, Myeloma, Myeloma Multiple
Register for Updates
TSC Biosample Repository and Natural History Database
NCT05676099
Recruiting
The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.
Gender:
ALL
Ages:
All
Trial Updated:
07/07/2025
Locations: Scottish Rite Hospital for Children, Dallas, Texas
Conditions: Tuberous Sclerosis, Lymphangioleiomyomatosis
Register for Updates
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Global Medical Research - M3 WR, Dallas, Texas +1 locations
Conditions: Primary IgA Nephropathy
Register for Updates
Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)
NCT05845710
Recruiting
The PERFORMANCE III study is a prospective, multicenter single-arm, open label study to evaluate the safety and effectiveness of the Neuroguard IEP® Direct System for the treatment of carotid artery stenosis in subjects at elevated risk for carotid endarterectomy (CEA). Eligible patients greater than or equal to 20 years of age and less than or equal to 80 years of age, are those who have been diagnosed with either de-novo atherosclerotic or post CEA restenotic lesion(s) in the internal carotid... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
07/07/2025
Locations: Baylor Scott and White Research Institute, Dallas, Texas +1 locations
Conditions: Carotid Stenosis, Carotid Artery Diseases
Register for Updates